A multi institutional phase II study of oral fludarabine and rituximab (F-R therapy) for patients with relapsed or refractory mantle cell lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2013
At a glance
- Drugs Fludarabine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 01 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 09 Apr 2012 Planned end date 1 Sep 2014 added as reported by University Hospital Medical Information Network - Japan.
- 13 Oct 2008 New trial record.